Have any questions? 706-721-6582 or cts@augusta.edu
The purpose of the study is to study how your immune system responds to the investigational drug called bempegaldesleukin (NKTR-214) when it is combined with the FDA approved drug pembrolizumab (KEYTRUDAź) in patients with locally advanced or metastatic solid tumors. The study will investigate the effect of the experimental combination of these study treatments on your tumor(s).